Outcomes associated with nonconcordance to national kidney foundation guideline recommendations for oral antidiabetic drug treatments in patients with concomitant type 2 diabetes and chronic kidney disease

Endocrine Practice

Volumn 20, Issue 3, 2014, Pages 221-231

  Chen, Shih Yin ^a   Lee, Yuan Chi ^a   Alas, Veronica ^a   Greene, Mallik ^b   Brixner, Diana ^c  

^a EVIDERA   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CHARLSON COMORBIDITY INDEX; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL ADMISSION; HUMAN; ICD-9-CM; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; YOUNG ADULT; ADOLESCENT; ANALYSIS; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; ORAL DRUG ADMINISTRATION; PROTOCOL COMPLIANCE; STATISTICAL MODEL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 84897830749     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/ep13269.or     Document Type: Article

References (25)

1. Milliman Inc., Finch K, Iwasaki K, Pyenson B. The cost and quality gap in diabetes care: an actuarial analysis. Available at: http://publications. milliman.com/publications/health-published/pdfs/cost-quality-gap-diabetes.pdf. Accessed September 4, 2013.
2. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs- 2011.pdf. Accessed September 4, 2013.
3. American Diabetes Association. Diabetes Statistics. Available at: http://www.diabetes.org/diabetes-basics/diabetes-statistics/. Accessed September 4, 2013.
4. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute. Circulation. 1999;100:1132-1133.
5. United States Renal Data System. USRDS annual data report 2011. Chronic kidney disease in general population. Available at: http://www.usrds.org/2011/ pdf/v1-ch01-11.pdf. Accessed September 4, 2013.
6. Chen SY, Siu K, Kovacs B, et al. Clinical and economic outcomes associated with National Kidney Foundation guideline-concordant oral antidiabetic drug treatment among type 2 diabetes patients with chronic kidney disease. Curr Med Res Opin. 2012;28:493-501.
7. Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl. 2005;98:S7-S10.
8. National Kidney Foundation. Diabetes and chronic kidney disease, 2012. Available at: http://www.kidney.org/atoz/pdf/diabetes.pdf. Accessed September 4, 2013.
9. United States Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease in the United States, Chapter 6. Available at: http://www.usrds.org/2011/pdf/v1-ch06-11.pdf. Accessed September 4, 2013.
10. Cohen A, Horton ES. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. Curr Med Res Opin. 2007;23:905-917.
11. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 suppl 2):S12-S154. Available at: http://www.kidney.org/ professionals/kdoqi/pdf/Diabetes-AJKD-FebSuppl-07.pdf. Accessed September 4, 2013.
12. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60:850-886.
13. National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 (2 suppl 1):S1-S266.
14. Rigalleau V, Lasseur C, Raffaitin C, et al. The Mayo Clinic quadratic equation improves the prediction of glomerular filtration rate in diabetic subjects. Nephrol Dial Transplant. 2007;22:813-818.
15. D'Hoore W, Bouckaert A, Tilquin C. Practical consideration on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol. 1996;49: 1429-1433.
16. Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol. 2000;29:891-898.
17. Ginde AA, Blanc PG, Lieberman RM, Camargo CA Jr. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord. 2008;8:4.
18. Mihaylova B, Briggs A, O'Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20:897-916.
19. Greene WH, ed. Econometric Analysis. 5th ed. Upper Saddle River, NJ: Pearson Education, Inc; 2003.
20. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795.
21. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27:136-142.
22. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American association of clinical endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement-executive summary. Endocr Pract. 2013;19:536-557.
23. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36(suppl 1): S11-S66.
24. Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006;19:161-167.
25. Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick ES. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. Diabetes Care. 2010;33:2310-2313.